NCT03288480View on ClinicalTrials.gov

A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

September 30, 2020

Study Completion Date

March 1, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

PT-112

This is a single arm study

Trial Locations (7)

19104

University of Pennsylvania, Philadelphia

32224

Mayo Clinic Cancer Center, Jacksonville

55905

Mayo Clinic Cancer Center, Rochester

78240

Texas Oncology San Antonio Medical Center, San Antonio

80220

Rocky Mountain Cancer Centers, Denver

85054

Mayo Clinic Cancer Center, Phoenix

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

Promontory Therapeutics Inc.

INDUSTRY

NCT03288480 - A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter